drugset / Trial / NCT05585567
A Preliminary Exploratory Study to Evaluate the Safety and Immunogenicity of Omicron Variant Bivalent Vaccine V-01-B5
RandomizedCrossoverOpen-labelPrevention
Summary
It is a single center, randomized, open-labeled, exploratory clinical study to evaluate the safety and immunogenicity of Recombinant SARS-CoV-2 Fusion Protein bivalent Vaccine V-01-B5 as a second booster in adults aged 18-59 years after vaccinated with 3-dose of inactivated vaccines.
Timeline
- Start
- 2022-09-16
- Primary completion
- 2022-10-14
- Completion
- 2023-09-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | V-01 | Vaccine | 10 ug | — |
| Subject | V-01-351 | Unknown | 10 ug | — |
| Subject | V-01-B5 | Vaccine | 10 ug | — |